

Indiana Women's Oncology

[View the current Indiana Women's Oncology Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24521-Indiana+Women%27s+Oncology.html)

(<http://www.bioportfolio.com/biocorporate/24521-Indiana+Women%27s+Oncology.html>)

Contact Details:

8301 Harcourt Road, Suite 201

Indianapolis

Indiana

46261

United States of America

Tel: (317) 415-6700

Fax: (317) 415-6707

Email: info@indianawomensoncology.com

We actively enroll patients in Indiana Women's Oncology (IWO) protocols. The IWO is a multicenter group which runs multiple therapeutic and diagnostic trials sponsored by the National Cancer Institute. These trials touch all aspects of care of the women with cancers of the reproductive tract. Current trials include developing new agents for ovarian cancer, utilizing antibodies to treat some ovarian cancers, determining the role of laparoscopic retroperitoneal lymphadenectomy in treating patients with advanced cervical cancer and many more. IWO also is very involved in clinical studies that are run by their own physicians. Several of these recent studies have won awards at both national and international medical/scientific meetings.

IWO is also highly active in basic science research trying to elaborate new prognostic indicators and tumor markers in women with cancers of the ovary, peritoneum, uterus (including endometrium and cervix), fallopian tube, vagina, vulva and breast. Recently our work on determining the size, shape and density of patients' cancer cell nuclei and their role in prognosis won an international award.

Surgical approaches utilized by the physicians of IWO include traditional approaches by abdominal incisions (laparotomy), as well as, advanced laparoscopic approaches where indicated. Customarily, gynecologic malignancies and pelvic reconstructive procedures have been approached by large abdominal incisions, but over the past decade laparoscopy has been able to be employed in select cases. Attention is taken to provide the best possible medical care for each individual patient treated by the physicians of IWO.

Recent Publications by Indiana Women's Oncology:



- [Imiquimod in vulvar Paget's disease: a case report.](#)
BACKGROUND: Vulvar Paget's disease is a relatively rare gynecologic... 4th February, 2009
Indiana Women's Oncology, Division of Gynecologic Oncology, St. Vincent- J Reprod Med. 2008 Oct;53(10):811-2.
- [Robotically assisted total laparoscopic radical trachelectomy for fertility sparing in stage IB1](#)

[adenosarcoma of the cervix.](#)

Adenosarcomas are rare cervical tumors with unknown optimal treatment... 28th January, 2009
Division of Gynecologic Oncology, Indiana Women's Oncology, St. Vincent- J Laparoendosc Adv Surg Tech A. 2008 Oct;18(5):727-9. ([DOI Direct Link](#))

- [Tunneled central venous catheters in a gynecologic oncology service: operative and short-term complications.](#)

PURPOSE: To determine the difference in the immediate complication rate... 11th June, 2008
Division of Gynecologic Oncology, Indiana Women's Oncology, St. Vincent- Eur J Gynaecol Oncol. 2008;29(2):141-3.

- [Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.](#)

OBJECTIVE: The purpose of this study was to analyze estrogen receptor... 11th June, 2008
Indiana Women's Oncology, St. Vincent Hospitals Indianapolis, IN, USA.- Eur J Gynaecol Oncol. 2008;29(2):126-8.

- [Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma.](#)

BACKGROUND: The purpose of this study was to determine whether vascular... 8th December, 2007
Indiana Women's Oncology, Division of Gynecologic Oncology, St. Vincent- J Surg Oncol. 2007 Nov 1;96(6):514-7. ([DOI Direct Link](#))

- [Extreme drug resistance is common after prior exposure to paclitaxel.](#)

OBJECTIVE: The platinum-free interval (PFI) is an important entity in the... 12th October, 2007
Indiana Women's Oncology, Division of Gynecologic Oncology, St. Vincent- Gynecol Oncol. 2007 Sep;106(3):538-40. Epub 2007 Jun 11. ([DOI Direct Link](#))

- [Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium.](#)

BACKGROUND: The purpose is to determine the rate of lymph node metastases... 5th October, 2007
Indiana Women's Oncology, St. Vincent Hospitals, Indianapolis, Indiana,- Int J Gynaecol Obstet. 2007 Jul;98(1):39-43. Epub 2007 May 8. ([DOI Direct Link](#))

- [5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report.](#)

A 31-year-old female was found to have FIGO Stage IIB squamous cell... 31st August, 2007
Indiana Women's Oncology, Division of Gynecol. Oncol. St. Vincent- Eur J Gynaecol Oncol. 2007;28(3):235.

- [Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer.](#)

BACKGROUND: The purpose of this study was to determine if serum prealbumin... 1st August, 2007
Indiana Women's Oncology, Indianapolis, IN 46260, USA.- Gynecol Oncol. 2007 Jul;106(1):128-31. Epub 2007 Apr 26. ([DOI Direct Link](#))

- [Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration.](#)

OBJECTIVE: To determine whether neoadjuvant cisplatin and 5-fluorouracil... 10th February, 2006
Indiana Women's Oncology, University of Iowa- Holden Comprehensive Cancer- Gynecol Oncol. 2006 Jan;100(1):53-7. Epub 2005 Oct 27. ([DOI Direct Link](#))

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership

username and password

- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

